Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 6

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Effect of transdermal hormone therapy on platelet haemostasis in menopausal women

100%
Stachowiak G., Pertynski T., Pertynska-Marczewska M.
Annals of Agricultural and Environmental Medicine
|
2015
|
tom 22
|
nr 1
2

Hyperthermia can differentially modulate the repair of doxorubicin-damaged DNA in normal and cancer cells

100%
Blasiak J., Widera K., Pertynski T.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr 1
Hyperthermia can modulate the action of many anticancer drugs, and DNA repair processes are temperature-dependent, but the character of this dependence in cancer and normal cells is largely unknown. This subject seems to be worth studying, because hyperthermia can assist cancer therapy. A 1-h incubation at 37°C of normal human pe­ripheral blood lymphocytes and human myelogenous leukemia cell line K562 with 0.5 juM doxorubicin gave significant level of DNA damage as assessed by the alkaline comet assay. The cells were then incubated in doxorubicin-free repair medium at 37°C or 41°C. The lymphocytes incubated at 37°C needed about 60 min to remove com­pletely the damage to their DNA, whereas at 41°C the time required for complete re­pair was shortened to 30 min. There was also a difference between the repair kinetics at 37°C and 41°C in cancer cells. Moreover, the kinetics were different in doxorubicin-sensitive and resistant cells. Therefore, hyperthermia may significantly affect the kinetics of DNA repair in drug-treated cells, but the magnitude of the effect may be different in normal and cancer cells. These features may be exploited in cancer chemotherapy to increase the effectiveness of the treatment and reduce unwanted ef­fects of anticancer drugs in normal cells and fight DNA repair-based drug resistance of cancer cells.
3

Parvovirus particles in a fetal-heart with myocarditis: ultrastructural and immunohistochemical study

100%
Respondek M., Bratosiewicz J., Pertynski T., Liberski P. P.
Archivum Immunologiae et Therapiae Experimentalis
|
1997
|
tom 45
|
nr 5-6
4

Anti- and prooxidative properties of hormonal therapy

100%
Stetkiewicz T., Makowski M., Pertynski T.
Acta Toxicologica
|
2007
|
tom 15
|
nr 1
5

Assessment of the influence of hormonal replacement therapy in postmenopausal women on reactive oxygen intermediates generation by neutrophils

76%
Stetkiewicz T., Polac I., Stachowiak G., Jedrzejczyk S., Makula A., Pertynski T.
Acta Toxicologica
|
2003
|
tom 11
|
nr 2
6

Analysis of the G-C polymorphism in the 5'-untranslated region of the RAD51 gene in breast cancer

64%
Blasiak J., Przybylowska K., Czechowska A., Zadrozny M., Pertynski T., Rykala J., Kolacinska A., Morawiec Z., Drzewoski J.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr 1
The breast cancer suppressor proteins BRCA1 and BRCA2 interact with RAD51, a protein essential for maintaining genomic stability by playing a central role in homology-dependent recombinational repair of the DNA double-strand breaks. Therefore, genetic variability in the RAD51 gene may contribute to the appearance and/or progression of breast cancer. A single nucleotide polymorphism in the 5 - un­translated region of RAD51 (a G to C substitution at position 135, the G/C polymor­phism) is reported to modulate breast cancer risk. We investigated the distribution of genotypes and frequency of alleles of the G/C polymorphism in breast cancer. Tumor tissues were obtained from postmenopausal women with node-negative and node-positive breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The G/C polymorphism was determined by PCR-based MvaI restriction fragment length polymorphism. The distribution of the genotypes of the G/C polymorphism did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the geno­type distribution and allele frequencies between node-positive and node-negative pa­tients. There were no significant differences between distributions of the genotypes in subgroups assigned to histological grades according to Scarf–Bloom–Richardson criteria and the distribution predicted by Hardy–Weinberg equilibrium (P > 0.05). Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer and so it may not be useful as an independent marker in this disease.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.